C.R. Bard

Morgan Stanley has published a report on C.R. Bard (NYSE: BCR). In the report, Morgan Stanley wrote, "After a strong 1Q11, Bard discussed managing down to meet their 14% earnings growth obligation. Now, after a pressured 2Q11, they may need to manage EPS up. Even if organic revenue does not...

Morgan Keegan is out with its report today on C.R. Bard (NYSE: BCR), maintaining Outperform. In a note to clients, Morgan Keegan writes, "This evening, Bard announced that it has reached agreements in principle with plaintiff's law firms to settle the majority of its existing hernia product claims...

J.P. Morgan is out with its report today on C.R. Bard (NYSE: BCR), raising its PT from $97 to $104. In a note to clients, J.P. Morgan writes, "We are raising our December 2011 price target to $104 from $97, with the new target based on 14.5x our CY12 EPS estimate (vs the prior 13.5x multiple)....

According to Piper Jaffray, C.R. Bard (NYSE: BCR) met Q1 revenue and exceeded EPS expectations with $700 M (up 7.4% cc) producing $1.51 in adjusted EPS. Piper Jaffray said that despite the $0.04-$0.05 earnings beat, management maintained 2011 EPS guidance at 14%, or $6.38/share, noting their...

Piper Jaffray has raised the price target on C.R. Bard (NYSE: BCR) from $93 to $104 and maintains its Neutral rating.

Piper Jaffray has raised the price target on C.R. Bard (NYSE: BCR) from $89 to $93 and maintains its Neutral rating.

C.R. Bard, Inc. (NYSE: BCR) reported 4Q results with in-line sales and EPS of $1.54 “versus our $1.50 estimate and Street consensus of $1.48,” Morgan Keegan reports. “Although the company picked up its SG&A investment in the quarter, it achieved EPS outperformance by the reinstatement of the R...

Morgan Stanley is initiating coverage on shares of C.R. Bard, Inc. (NYSE: BCR) with an EW rating. “Bard's premium multiple of 15x (vs. peers at 13x) is justified, given that it is insulated from structural pressures facing high-end implantable providers, continues to offer top-quartile growth, and...

For 2011, Deutsche Bank reports that C.R. Bard, Inc. (NYSE: BCR) sales growth guidance is likely wider and lighter than expected, but is likely to be overshadowed by higher EPS guidance. “A $750M repurchase adds 4%-pts to arrive at 14% EPS growth,” Deutsche Bank writes. “On our higher EPS, we're...

J.P. Morgan released its report today on C.R. Bard (NYSE: BCR) after BCR's annual Investor meeting Monday. In a note to clients, J.P. Morgan writes, "We are raising our December 2011 price target to $95 from $93, with the new target based on the same 13.5x P/E multiple applied to our CY12 EPS...

C.R. Bard, Inc. (NYSE: BCR) reported 3Q results with slightly lower sales and EPS of $1.43 versus Morgan Keegan's $1.39 estimate. “Given the challenging global health care markets, we view Bard's results favorably,” Morgan Keegan writes. “Although management did not note any improvements in...